Chimeric Antigen Receptor T-cells clinical trials
How each study uses Chimeric Antigen Receptor T-cells is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Chimeric Antigen Receptor T-cells studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
68 studies that test it; most in 2025 (13)
| Year | Studies |
|---|---|
| 2016 | 2 |
| 2017 | 5 |
| 2018 | 4 |
| 2019 | 3 |
| 2020 | 3 |
| 2021 | 8 |
| 2022 | 5 |
| 2023 | 9 |
| 2024 | 11 |
| 2025 | 13 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 60
City of Hope Medical Center (5) · Zhejiang University (4) · Memorial Sloan Kettering Cancer Center (3) · The Affiliated Hospital of Xuzhou Medical University (3) · Shanghai Changzheng Hospital (2) · Shenzhen Geno-Immune Medical Institute (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Shenzhen University General Hospital (2)
Often tested with
Tested in the same studies.
Chimeric Antigen Receptor T-Cell Therapy|Chimeric Antigen Receptor T-cell Therapy (14) · Cyclophosphamide (8) · Fludarabine (7) · Odronextamab (3) · Conditioning Chemotherapy (2) · Fludarabine phosphate (2) · Etoposide (2) · Dexamethasone (2)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 14, 1 in phase 3
Studies that test Chimeric Antigen Receptor T-cells, phase 3 first.
- May 2027A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer PatientsPhase 3 · Suzhou Immunofoco Biotechnology Co., Ltd
- Dec 2026Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCLPhase 2 · H. Lee Moffitt Cancer Center and Research Institute
- Dec 2026GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor MalignanciesPhase 1 · National Cancer Institute (NCI)
- Jan 2027a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell LeukemiaEarly Phase 1 · Shanghai Changzheng Hospital
- Jan 2027Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell LymphomaEarly Phase 1 · City of Hope Medical Center
- Jan 2027HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal MetastasesPhase 1 · City of Hope Medical Center
- Feb 2027Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell TherapyPhase 2 · H. Lee Moffitt Cancer Center and Research Institute
- Jun 2027Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell TherapyPhase 2 · Mayo Clinic
- Aug 2027Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic LeukemiaPhase 1 · Jonsson Comprehensive Cancer Center
- Aug 2027A Study of CAR-T Cells in Subjects with Autoimmune DiseasesEarly Phase 1 · Zhejiang University
Studies
Open first, then newest update. How each study uses Chimeric Antigen Receptor T-cells is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 68
- Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or PlasmacytomaNot yet recruitingPhase 1/2Shenzhen Geno-Immune Medical InstituteNCT06429150Written as CAR-T cells
- Multi-CAR T Cell Therapy in the Treatment of Multiple MyelomaNot yet recruitingPhase 1/2Shenzhen Geno-Immune Medical InstituteNCT03271632Written as CAR T cells
- Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant AstrocytomaRecruitingPhase 1City of Hope Medical CenterNCT06815029Written as Chimeric Antigen Receptor T-Cell Therapy
- Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell TherapyRecruitingPhase 2Mayo ClinicNCT06834373Written as Chimeric Antigen Receptor T-Cell Therapy
- GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor MalignanciesRecruitingPhase 1National Cancer Institute (NCI)NCT05003895Written as CAR-T cell
- A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple MyelomaNot yet recruitingPhase 1/2Centre Hospitalier Universitaire de Saint EtienneNCT07612787Written as CAR-T cells
- Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell TherapyRecruitingPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT05757219Written as Chimeric antigen receptor (CAR) T-cell therapy
- Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-TRecruitingPhase 2University of WashingtonNCT06784726Written as Chimeric Antigen Receptor T-Cell Therapy
- Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian CancerRecruitingPhase 1City of Hope Medical CenterNCT05225363Written as Chimeric Antigen Receptor T-cells
- CAR-T Cell Therapy for ALLRecruitingEarly Phase 1Dr. Zaineb AkramNCT07695012Written as CAR-T cell infusion
- Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell TherapyRecruitingPhase 2University of California, DavisNCT06854159Written as Chimeric Antigen Receptor T-Cell Therapy
- CD30 CAR-T Cells for Low Risk Relapsed Classical Hodgkin LymphomaNot yet recruitingPhase 1New York Medical CollegeNCT07575893Written as CD30+ CAR T-cells
- Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic MalignanciesRecruitingPhase 1/2Shenzhen University General HospitalNCT07584889Written as CAR-T cell
- Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCLRecruitingPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT06104592Written as Chimeric Antigen Receptor T-Cell Therapy
- Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.RecruitingPhase 1Tcelltech Inc.NCT06482905Written as Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103
- Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALLRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT06481241Written as CAR-T cells
- Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALLRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT06481228Written as CAR-T cells
- A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin LymphomaRecruitingPhase 2/3University of BirminghamNCT05991388Written as CAR T-cells (TBC)
- Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell LymphomaRecruitingEarly Phase 1City of Hope Medical CenterNCT05800405Written as Chimeric Antigen Receptor T-Cell Therapy
- A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG11001 )RecruitingPhase 1Tongji HospitalNCT07053670Written as CAR T cells
See all 68 studies that test Chimeric Antigen Receptor T-cells →
Given beside what is tested · 7 — Chimeric Antigen Receptor T-cells is usual care or a partner of the new treatment
- IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCLRecruitingPhase 1/2University of Texas Southwestern Medical CenterNCT06768905Written as CAR-T cell
- Clinical Study of UTAA07 Injection in the Treatment of Hematologic and Lymphatic Systemic MalignanciesRecruitingEarly Phase 1PersonGen BioTherapeutics (Suzhou) Co., Ltd.NCT07338604Written as CAR-T cell infusion
- CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).RecruitingPhase 2Lazaros LekakisNCT05260957Written as CAR-T Cell Therapy
- Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell LymphomaSuspendedPhase 1University of California, DavisNCT05052528Written as Chimeric Antigen Receptor T-Cell Therapy
- Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell LymphomaActive, not recruitingEarly Phase 1Memorial Sloan Kettering Cancer CenterNCT04512716Written as CAR T-cell
- Duvelisib Following Chimeric Antigen Receptor T-Cell TherapyActive, not recruitingPhase 1Washington University School of MedicineNCT05044039Written as CAR T-cells
- CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell MalignanciesActive, not recruitingPhase 1Stanford UniversityNCT03233854Written as Chimeric Antigen Receptor T-Cell Therapy